Given AA's ability to induce clinically significant improvements in overall survival, TTP, pain control, and prostate-specific antigen (PSA) responses in both docetaxel refractory and naïve patients, it has become one of the most frequently used second line hormonal maneuvers. 4, 5 Additionally, its tolerability and ease of oral administration have made it a frequent choice prior to chemotherapy for mCRPC.
AA may also undergo SLCO-mediated transport given its steroidal structure. The latter is supported by findings from Mostaghel et al 6 that genetic variation in SLCO genes was associated with intraprostatic AA levels and that LNCaP cells overexpressing SLCO had higher intracellular levels of AA. More efficient transport of AA or of other substrates such as DHEAS may play a role in the acquired resistance to AA that almost all patients experience.
The objective of our study was to assess whether concurrent statin use influenced the clinical efficacy of AA in patients with advanced castration-resistant prostate cancer (CRPC). Based on initial in vitro work demonstrating a negative interaction, we hypothesized that concurrent statin use would counteract AA's antitumor effects.
After seeing a contrary trend to benefit in the initial Dana-Farber
Cancer Institute (DFCI) cohort, we attempted to validate the findings using a second institutional cohort of patients from Johns Hopkins University (JHU).
| MATERIALS, PATIENTS, AND METHODS

| Preclinical studies
| Cell lines and reagents
The hormone sensitive prostate cancer cell lines, LNCaP, and 22RV1, were employed in the study. LNCaP and 22RV1 cells were maintained in RPMI 1640 and supplemented with 10% FBS and antibiotics. The stable inducible shSLCO2B1-expressing cell lines were used as previously described and maintained in medium containing puromycin. 1 All cell lines were regularly screened for mycoplasma (Sigma Venor GeM Mycoplasma Detection Kit). Atorvastatin was purchased from Santa Cruz Biotechnology. Abiraterone acetate, fluvastatin, pravastatin, and simvastatin were purchased from Selleckchem.
| Cell proliferation assay
Cell proliferation was determined using the WST-1 assay (Roche, 3 | RESULTS
| Preclinical studies
Given that AA may also use SLCO2B1 as a transporter, we evaluated the effects of AA and statins alone and in combination in prostate cancer cell lines. The key finding was that AA's effect on prostate cancer cell proliferation is SLCO2B1 dependent. Knockdown of SLCO2B1 (shSLCO2B1) in both 22RV1 and LNCaP cells attenuated AA's inhibition of cell growth ( Figure 1A ). These findings suggest that AA's efficacy depends on SLCO2B1 transport into cells. 7 When evaluating for competition between AA and statins for uptake, we observed that atorvastatin attenuated AA's inhibition of the prostate cancer cell proliferation and was SLCO2B1 dependent ( Figure 1B ).
When SLCO2B1 is knocked down, AA's inhibitory effects on cell growth are attenuated. The greatest degree of AA's inhibition of cell growth occurs in the absence of statin but in the presence of intact SLCO2B1. In the presence of statin, inhibition of cell proliferation by AA is decreased and is concentration dependent ( Figure 1B ).
To evaluate differences in inhibition among the different statins,
we compared the effects of four common statins ( Figure 1C ,D).
Fluvastatin and simvastatin seemed to attenuate AA's inhibition of cancer growth the most with pravastatin being less inhibitory.
| Clinical observations
Based on the preclinical results showing antagonism, we hypothesized that statins may compete with AA for influx by SLCO2B1, which could negatively impact drug efficacy and treatment duration.
| DFCI cohort
We identified 224 patients treated with AA between 2008 and 2015 at DFCI who were eligible for analysis ( Table 1) . The majority of patients (96%) had metastatic disease at the time of AA initiation. Of these, 26%
had received prior docetaxel and 7% had had prior enzalutamide.
Nearly half were statin users (41% We observed a trend toward longer (rather than shorter) AA duration in statin users: 14.2 versus 9.2 months (HR 0.79, 95%CI: 0.57-1.09, P = 0.14, Figure 2A , Table 2 ). Similarly, in patients whose disease was naïve to docetaxel or enzalutamide, there was a trend toward longer AA use if patients were taking concurrent statins (HR 0.76; 95%CI: 0.50-1.15, Figure 2B ). In univariate analysis, prior docetaxel (P = 0.0001) or enzalutamide (P = 0.0001) use was significantly associated with shorter AA duration ( Table 2) . Adjusting for prior use of docetaxel or enzalutamide and site of metastases did not alter the relationship between statin use and AA duration (HR 0.81, 95%CI: 0.58-1.11, P = 0.18; Table 2 ). PSA at AA start was similar between the non-users and users (20.3 vs 16.9 ng/dL, Table 1 ), and similar declines on AA therapy were achieved. 
| JHU cohort
PSA at diagnosis Figure 2C ) in the statin users versus non-users. In patients whose disease was naïve to docetaxel and enzalutamide, the impact of statin use on duration of AA was similar to that observed in the DFCI cohort (HR 0.79; 95%CI:
0.57-1.10, Figure 2D ). Adjusting for prior use of docetaxel, enzalutamide, and site of metastases confirmed the lack of association as in the univariate analysis (P = 0.52, HR 0.92, 95%
CI: 0.70, 1.20, Table 2 ). PSA at AA start was similar between the non-users and users (33.1 vs 35.6 ng/dL, Table 1 ), and both cohorts achieved a similar degree of PSA decline.
In reviewing the clinico-demographic data (Table 1) , we observed that the JHU patients appeared to have more advanced disease both at diagnosis and at AA initiation. They had higher
Gleason grades, higher clinical T stages, and more nodal and metastatic disease at diagnosis. JHU patients also had a higher median PSA at time of AA initiation for CRPC (34.5 vs 20.1 ng/dL).
Additionally, the proportion of JHU patients with poorer prognosis as defined by presence of visceral metastases was also higher at AA initiation (19% vs 10%). Given these significant differences and potential heterogeneity between disease states across these two institutional cohorts, we summarized the clinical outcomes of these patients separately by center. Duration of AA therapy (8.3 vs 10.7 months) and overall survival (24.7 vs 36.6 months) were significantly shorter for JHU patients compared to DFCI patients ( Figure 3 , Table 3 ).
| DISCUSSION
Prior preclinical work and retrospective studies in patients with HSPC revealed how statins may compete with androgen uptake by the SLCO family of transporters. Similarly, in vitro studies showed a possible negative interaction between statins and AA, which we postulated might be due to competitive inhibition of SLCO2B1.
Thus, we hypothesized that statins would compete with AA uptake by the prostate cancer cell and that patients on concurrent statins would have worse outcomes. However, contrary to our initial hypothesis, we observed a trend toward longer (rather than We considered several explanations for the disparate results between the cohorts. First, the positive trend observed in the DFCI cohort was not statistically significant and thus, there may be no did not find any difference in clinical benefit among the 19% of patients on statins compared to the non-users. 8 Alternatively, both the German study and ours may be limited by sample sizes too small to definitively detect the benefit of concurrent statin use. However, the positive trend to benefit that we observed in the DFCI cohort is plausible for several reasons. In our previous study, where we assessed the association of TTP on ADT, we found that statin users had a significantly longer TTP on ADT with a similar effect size The SLCO (OATP) transporters are expressed physiologically on multiple cells such as hepatocytes and mediate uptake of several hormones and drugs. 12 SLCO1B1 and SLCO1B3 appear to be liver specific whereas SLCO2B1 appears to be more ubiquitously expressed throughout multiple organs of the body. 12 One study observed that abiraterone and its metabolites inhibited the OATP1B1 (SLCO1B1) transporter in human hepatocytes in vitro but based on the calculated in vivo inhibition potential, these effects were thought to be negligible. 13 In summary, contrary to our hypothesis derived from preclinical studies, there was a trend toward longer AA duration in statin users in the DFCI cohort. While this finding was not supported in the entire JHU cohort, who generally had more advanced disease, the subset of patients whose disease was naïve to enzalutamide and 
